Orchid, Struggling to Escape Delisting, Plans to Appeal Nasdaq Decision

Jan 13, 2003

NEW YORK, Jan. 13-Orchid Biosciences has received a delisting warning notice from Nasdaq, the company said today.

Orchid's stock has traded below $1.00 since Sept. 3, which means it is in violation of the rules for continued listing on the exchange.

Orchid plans to request a hearing regarding the decision, and its stock will continue to be traded pending the outcome of that hearing.

The company is considering a reverse stock split, pending shareholder approval.

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.